Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 70 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Niraparib with pembrolizumab maintenance therapy for metastatic stage III or IV non-small cell lung cancer	Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Pembrolizumab (Keytruda) for advanced gastric or gastroesophageal junction adenocarcinoma – first line	Pembrolizumab (Keytruda; MK-3475)	Gastric cancer , Gastro-oesophageal junction cancer	Gastrointestinal Cancer	2017	View \| Download
Pembrolizumab (KEYTRUDA) for advanced, metastatic oesophageal cancer – second line	Pembrolizumab (Keytruda; MK-3475)	Gastro-oesophageal junction cancer , Oesophageal cancer	Gastrointestinal Cancer , Head and Neck Cancer	2017	View \| Download
Pembrolizumab (Keytruda) for metastatic castration‐resistant prostate	Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2017	View \| Download
Pembrolizumab (Keytruda) for non‐small cell lung cancer - first line, previously untreated	Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Pembrolizumab (Keytruda) for relapsed/refractory classical Hodgkin lymphoma	Pembrolizumab (Keytruda; MK-3475)	Hodgkin lymphoma	Haematological Cancer and Lymphomas	2018	View \| Download
Pembrolizumab (Keytruda) for triple negative breast cancer	Pembrolizumab (Keytruda; MK-3475)	Breast cancer	Breast Cancer	2017	View \| Download
Pembrolizumab (KEYTRUDA) in combination with carboplatin-paclitaxel/Nab-paclitaxel for metastatic squamous non small cell lung cancer, first line	Carboplatin (Paraplatin) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) , Paclitaxel (Taxol; paclitaxel albumin) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Pembrolizumab addition to chemotherapy, followed by maintenance with olaparib for BRCA non-mutated advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer – First-line	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2020	View \| Download
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer	Pembrolizumab (Keytruda; MK-3475)	Urothelial cancer	Urological Cancer	2024	View \| Download